International Assets Investment Management LLC Purchases 13,648 Shares of Organon & Co. (NYSE:OGN)

International Assets Investment Management LLC lifted its holdings in Organon & Co. (NYSE:OGN) by 1,441.2% in the 4th quarter, HoldingsChannel.com reports. The fund owned 14,595 shares of the company’s stock after buying an additional 13,648 shares during the period. International Assets Investment Management LLC’s holdings in Organon & Co. were worth $210,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Nordea Investment Management AB grew its stake in Organon & Co. by 2,016.0% during the fourth quarter. Nordea Investment Management AB now owns 3,128,810 shares of the company’s stock worth $44,648,000 after purchasing an additional 2,980,945 shares during the period. Invesco Ltd. increased its stake in Organon & Co. by 23.7% in the third quarter. Invesco Ltd. now owns 10,240,630 shares of the company’s stock valued at $177,777,000 after purchasing an additional 1,963,682 shares in the last quarter. Sound Income Strategies LLC raised its holdings in shares of Organon & Co. by 140,626.7% during the fourth quarter. Sound Income Strategies LLC now owns 489,729 shares of the company’s stock valued at $7,062,000 after purchasing an additional 489,381 shares during the period. FMR LLC boosted its position in shares of Organon & Co. by 28.3% during the 3rd quarter. FMR LLC now owns 2,189,693 shares of the company’s stock worth $38,013,000 after purchasing an additional 483,257 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in shares of Organon & Co. by 4.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 9,280,300 shares of the company’s stock valued at $161,106,000 after buying an additional 436,034 shares during the period. 77.43% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group increased their price target on Organon & Co. from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Tuesday, February 20th.

Organon & Co. Trading Up 0.7 %

OGN opened at $18.55 on Monday. Organon & Co. has a 1-year low of $10.84 and a 1-year high of $24.79. The company has a market cap of $4.74 billion, a price-to-earnings ratio of 4.64, a PEG ratio of 0.88 and a beta of 0.83. The company’s fifty day moving average price is $18.14 and its two-hundred day moving average price is $15.68.

Organon & Co. (NYSE:OGN) last posted its earnings results on Thursday, February 15th. The company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.14. Organon & Co. had a net margin of 16.33% and a negative return on equity of 212.00%. The company had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.55 billion. As a group, equities analysts forecast that Organon & Co. will post 4.08 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, March 14th. Stockholders of record on Monday, February 26th were issued a $0.28 dividend. The ex-dividend date of this dividend was Friday, February 23rd. This represents a $1.12 dividend on an annualized basis and a dividend yield of 6.04%. Organon & Co.’s dividend payout ratio is presently 28.00%.

Insider Activity at Organon & Co.

In related news, insider Kirke Weaver purchased 2,720 shares of the stock in a transaction that occurred on Thursday, February 22nd. The stock was acquired at an average cost of $18.36 per share, with a total value of $49,939.20. Following the transaction, the insider now owns 15,181 shares of the company’s stock, valued at approximately $278,723.16. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.17% of the stock is owned by insiders.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.